Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 38 of 109, showing 5 Applications out of 545 total, starting on record 186, ending on 190

# Protocol No Study Title Investigator(s) & Site(s)

186.

ECCT/22/09/01   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Godfrey Allan Otieno
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Kombewa Clinical Research Centre (Kisumu county)
 
View

187.

ECCT/22/07/01   GBT021601-021 Study
    A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Berhnards Ragama Ogutu
3. Videlis Nduba
4. Berhnards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county)
 
View

188.

ECCT/22/06/01   The INSIGHT cohort
      A cohort for evaluation of open-label PrEP delivery and PrEP preferences among African women        
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP, LUMUMBA SUBCOUNTY HOSPITAL
 
View

189.

ECCT/22/06/02   Mitapivat - AG348-C-020
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.   
Principal Investigator(s)
1. Lucas Otieno Tina
2. Bernhards Ragama Ogutu
3. Prof Jessie N Githanga
4. Videlis N Nduba
5. Janet N/A Oyieko
6. Allan Godfrey Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Strathmore University Medical Centre (Nairobi City county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Kombewa Clinical Research Centre (Kisumu county)
 
View

190.

ECCT/22/05/01   VICTORION-2 PREVENT
    A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with   established cardiovascular disease   
Principal Investigator(s)
1. Anthony Gikonyo
2. ELIJAH SAMMY NYAINDA OGOLA
Site(s) in Kenya
1. The Karen Hospital (Nairobi City county)
2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county)
 
View